An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease
- Focus Pharmacokinetics
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Status changed from recruiting to completed.
- 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.